Results 181 to 190 of about 14,094 (223)

Semaglutide Inhibits Osteoblast Ferroptosis Induced by Diabetic Periodontitis via Modulating the Wnt5a/Ror2/p38 MAPK Signaling Pathway. [PDF]

Drug Des Devel Ther
Zhang Z, Niu D, Qiu W, Feng H, Jia L, Zhou W.   +5 more
europepmc   +1 more source

Ocular Manifestations of Metabolic Syndrome: A Systemic Vascular Phenotype

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Context Metabolic syndrome (MetS) is defined by central obesity, insulin resistance, hypertension and dyslipidemia. MetS affects over one‐third of US adults. Beyond its cardiovascular burden, MetS has clinically relevant associations with ocular health and may contribute to a systemic vascular and neuro‐metabolic phenotype involving the retina,
Ron T. Varghese, Ansu A. John
wiley   +1 more source

Efficacy of CagriSema for Reaching Anthropometric Treatment Targets and Cardiometabolic Outcomes: A Secondary, Post hoc Analysis of REDEFINE 1

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To assess the added value of absolute anthropometric targets alongside percentage weight loss in the clinical management of obesity. Materials and Methods The phase 3a, 68‐week REDEFINE 1 trial randomised adults without diabetes with BMI ≥ 30 kg/m2, or ≥ 27 kg/m2 with ≥ 1 obesity‐related complication, to once‐weekly CagriSema 2.4 mg/2.4 ...
Luca Busetto, Cynthia Osorto Contreras, Mikkel Hovden Christensen, Timothy W. Garvey, Deborah B. Horn, Barbara McGowan, Claire Prener Miller, Volker Schnecke, Carel W. le Roux   +8 more
wiley   +1 more source

A Review of the Oral Semaglutide in Adults with Overweight or Obesity (OASIS) Trials Evaluating Oral Semaglutide (Wegovy) for Chronic Weight Management in Adults With Overweight or Obesity. [PDF]

Cureus
Ojinna BT, Tariq S, Agho O, Channa R, Singh G.   +4 more
europepmc   +1 more source

Intensified multifactorial intervention leads to long‐term benefit on kidney outcomes in advanced diabetic kidney disease: A 10‐year follow‐up of the DNETT‐Japan trial

Journal of Diabetes Investigation, EarlyView.
ABSTRACT Introduction Despite recent therapeutic advances in slowing kidney disease progression, the long‐term efficacy of intensive multifactorial treatment in advanced‐stage diabetic kidney disease remains unclear. We assessed long‐term kidney outcomes through the 5‐year Diabetic Nephropathy Remission and Regression Team Trial in Japan (DNETT‐Japan ...
Kenichi Shikata, Satoshi Miyamoto, Masakazu Haneda, Hiroki Hosoi, Kota Sakamoto, Yoshiki Suzuki, Daisuke Suzuki, Hitoshi Ishida, Hiroaki Akai, Yasuhiko Tomino, Takashi Uzu, Motonobu Nishimura, Hiromi Kuramoto, Michihiro Yoshida, Daisuke Ogawa, Toshiharu Ninomiya, Hirofumi Makino, the Diabetic Nephropathy Remission and Regression Team Trial in Japan (DNETT‐Japan) collaborative group   +17 more
wiley   +1 more source

Dysesthesia associated with GLP-1 agonist therapies: data-mining analysis and literature review. [PDF]

Eur J Clin Pharmacol
Laroche ML, Géniaux H, Jardou M.
europepmc   +1 more source

Efficacy and Safety of Oral Semaglutide in the Management of Diabetes and Obesity: A Comprehensive Meta-analysis of Real-world Evidence. [PDF]

touchREV Endocrinol
Jena S, Jindal R, Dutta D, Kamrul-Hasan ABM, Mahajan K.   +4 more
europepmc   +1 more source

Unmasking counterfeit semaglutide: analysis of real-world safety data from EudraVigilance. [PDF]

Front Pharmacol
Zinzi A, Gaio M, Ruggiero R, Mascolo A, Riemma MA, Cipriani M, Laino LV, Berrino L, Rossi F, Capuano A.   +9 more
europepmc   +1 more source

Comment on Rossing et al. Nuances in Interpretation: Assessing the Interaction Between Semaglutide and MRAs in the FLOW Trial. [PDF]

Diabetes Care
Liu Q, Yang JF, Wang ZG.
europepmc   +1 more source

Gallbladder‐Related Adverse Events With Semaglutide 2.4 mg: Pooled Analysis of Placebo‐Controlled STEP Trials

Diabetes, Obesity and Metabolism, EarlyView.
Mika Ukkonen, Antti Kivivuori, Peter Starckjohann, Pekka Lammi, Anna Junttila, Valtteri Panula   +5 more
wiley   +1 more source